SCHEMBL20047023

SCHEMBL20047023

COc1cccc(-c2ccc3c(c2)CCN(S(=O)(=O)c2c(C)cc(I)cc2C)C3)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.49
TMEM97 Q5BJF2 3/20 0.49
SIGMAR1 Q99720 3/20 0.49
HTR1A P08908 2/20 0.49
DRD4 P21917 2/20 0.49
HTR2C P28335 2/20 0.49
HTR2B P41595 2/20 0.49
SLC6A3 Q01959 2/20 0.49
CHRM2 P08172 1/20 0.49
CHRM3 P20309 1/20 0.49
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
DRD3 P35462 1/20 0.49
PKM P14618 2/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20047172 0.92 TMEM97 (0.51) AKR1C3TMEM97SIGMAR1HTR1ADRD4
SCHEMBL20047027 0.91 PKM (0.51) AKR1C3PKMAKR1C1PPARGPPARD
SCHEMBL20047032 0.85 KMT2A (0.47) AKR1C3OPRK1AKR1C1CYP11B1CYP11B2
SCHEMBL20047028 0.83 SMN1; SMN2 (0.47) AKR1C3PKMCYP11B1CYP11B2SMN1; SMN2
SCHEMBL20047031 0.83 AKR1C3 (0.48) AKR1C3OPRK1AKR1C1CYP11B1CYP11B2
SCHEMBL20047173 0.82 PKM (0.53) AKR1C3PKMOPRK1SMN1; SMN2MEN1
SCHEMBL20047029 0.82 CYP11B1 (0.50) CYP11B1CYP11B2CYP3A4CYP2C19
SCHEMBL20047024 0.81 CHRM5 (0.41) AKR1C3PKMOPRK1AKR1C1SMN1; SMN2
SCHEMBL20047020 0.80 MEN1 (0.40) AKR1C3OPRK1AKR1C1CYP11B1CYP11B2
SCHEMBL22484651 0.79 L3MBTL1 (0.53) AKR1C3OPRK1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017223514-A9 LXR INVERSE AGONISTS FOR TREATMENT OF CANCER SAINT LOUIS UNIVERSITY (US) 2018-04-12 WO disclosed